Tainá Schons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tainá Schons has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Adriane Ribeiro Rosa
Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre (HCPA), Porto Alegre, RS, Brazil; Department of Pharmacology and Graduate Program of Pharmacology and Therapeutics, Institute for Basic Medical Science, University Federal do Rio Grande, do Sul, Brazil; Graduate Program in Psychiatry and Behavioral Sciences, School of Medicine, University Federal of Rio Grande doSul, (UFRGS), Porto Alegre, RS, Brazil
3 shared publications - Hemelin Resende Farias
Department of Biochemistry, Basic Health Sciences Institute, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
3 shared publications - Jade de Oliveira
Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde (ICBS), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
3 shared publications - Matheus Scarpatto Rodrigues
University of Pittsburgh, Pittsburgh, PA USA
3 shared publications - Andreza Fabro de Bem
Universidade de Brasília, Brasília Brazil
2 shared publications - Gabriel Rocha
Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
2 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by Springer Nature
A Beginner-Friendly Workflow for Untargeted LC–MS Metabolomics Data Processing from Raw Data to Differential Feature Analysis v1
Untargeted LC–MS metabolomics generates thousands of detected features that require multiple preprocessing and quality control steps before statistical interpretation. Although several software packages are available, reproducing a complete data processing workflow remains challenging for researchers with limited experience in computational metabolomics. This protocol provides a beginner-friendly, step-by-step workflow for untargeted LC–MS metabolomics data processing, starting from raw mass spectrometry files and ending with differential feature analysis. The workflow includes raw data conversion, feature detection using MZmine 4, quality assessment, blank and QC filtering, missing value imputation, total-sum normalization, exploratory PCA, and differential abundance analysis using linear models with empirical Bayes moderation (limma). The protocol emphasizes reproducibility by including verification steps, expected outputs, and quality-control checkpoints throughout the analysis. The final outputs consist of normalized feature matrices, quality-control summaries, statistical result tables, and publication-ready visualizations. Metabolite annotation is intentionally addressed in a separate protocol dedicated to MS/MS-based annotation workflows.
- 24 June 2026
- Published by Springer Nature
Open AccessA Beginner-Friendly Workflow for Untargeted LC–MS Metabolomics Data Processing from Raw Data to Differential Feature Analysis v1
Untargeted LC–MS metabolomics generates thousands of detected features that require multiple preprocessing and quality control steps before statistical interpretation. Although several software packages are available, reproducing a complete data processing workflow remains challenging for researchers with limited experience in computational metabolomics. This protocol provides a beginner-friendly, step-by-step workflow for untargeted LC–MS metabolomics data processing, starting from raw mass spectrometry files and ending with differential feature analysis. The workflow includes raw data conversion, feature detection using MZmine 4, quality assessment, blank and QC filtering, missing value imputation, total-sum normalization, exploratory PCA, and differential abundance analysis using linear models with empirical Bayes moderation (limma). The protocol emphasizes reproducibility by including verification steps, expected outputs, and quality-control checkpoints throughout the analysis. The final outputs consist of normalized feature matrices, quality-control summaries, statistical result tables, and publication-ready visualizations. Metabolite annotation is intentionally addressed in a separate protocol dedicated to MS/MS-based annotation workflows.
- Open Access
- 24 January 2026
- Published by Springer Nature in Neurochemical Research
- Vol. 51 (1) , 60
Metformin Ameliorates Cognitive Deficits and Neuroinflammation in a Mouse Model of Familial Hypercholesterolemia
Familial hypercholesterolemia (FH), caused by mutations in the low-density lipoprotein receptor (LDLr) gene, has been increasingly associated with neurodegenerative and mood disorders. Studies with LDLR knockout mice (LDLr −/− ) showed that neuroinflammation is a key event in FH-related brain dysfunction. Because mTOR inhibition has been shown to mitigate brain alterations in this model, we hypothesized that metformin, a drug reported to influence cellular energy metabolism, could attenuate FH-associated brain changes. To test this, adult LDLr −/− mice received daily oral doses of metformin (200 mg/Kg) or vehicle for 30 days. During the final week, behavioral assessments were conducted, including the open-field test, novel object recognition and object reallocation tasks, and the tail suspension test (depressive-like behavior). Body weight, total cholesterol and glucose plasma levels were analyzed. Hippocampal astrocyte and microglial density, as well as the expression of genes related to neuroinflammation and synaptic plasticity, were evaluated. Metformin did not alter total cholesterol levels but significantly improved cognitive performance and reduced depressive-like behavior. The treatment also attenuated hippocampal astrogliosis without affecting microglial reactivity. Molecular analysis revealed reduced hippocampal TGF-β gene expression and increased PSD-95 gene expression and protein content in metformin-treated LDLr −/− mice. Although a slight, non-significant reduction in the phosphorylated-to-total mTOR ratio was detected, no clear evidence of AMPK/mTOR pathway modulation was observed. Overall, metformin improved memory function and astrocyte reactivity in LDLr −/− mice independently of cholesterol reduction and without demonstrable involvement of the AMPK/mTOR pathway, suggesting its potential as a therapeutic strategy for FH-associated brain dysfunction.
- 24 January 2026
- Published by Springer Nature in Neurochemical Research
- Vol. 51 (1) , 60
Open AccessMetformin Ameliorates Cognitive Deficits and Neuroinflammation in a Mouse Model of Familial Hypercholesterolemia
Familial hypercholesterolemia (FH), caused by mutations in the low-density lipoprotein receptor (LDLr) gene, has been increasingly associated with neurodegenerative and mood disorders. Studies with LDLR knockout mice (LDLr −/− ) showed that neuroinflammation is a key event in FH-related brain dysfunction. Because mTOR inhibition has been shown to mitigate brain alterations in this model, we hypothesized that metformin, a drug reported to influence cellular energy metabolism, could attenuate FH-associated brain changes. To test this, adult LDLr −/− mice received daily oral doses of metformin (200 mg/Kg) or vehicle for 30 days. During the final week, behavioral assessments were conducted, including the open-field test, novel object recognition and object reallocation tasks, and the tail suspension test (depressive-like behavior). Body weight, total cholesterol and glucose plasma levels were analyzed. Hippocampal astrocyte and microglial density, as well as the expression of genes related to neuroinflammation and synaptic plasticity, were evaluated. Metformin did not alter total cholesterol levels but significantly improved cognitive performance and reduced depressive-like behavior. The treatment also attenuated hippocampal astrogliosis without affecting microglial reactivity. Molecular analysis revealed reduced hippocampal TGF-β gene expression and increased PSD-95 gene expression and protein content in metformin-treated LDLr −/− mice. Although a slight, non-significant reduction in the phosphorylated-to-total mTOR ratio was detected, no clear evidence of AMPK/mTOR pathway modulation was observed. Overall, metformin improved memory function and astrocyte reactivity in LDLr −/− mice independently of cholesterol reduction and without demonstrable involvement of the AMPK/mTOR pathway, suggesting its potential as a therapeutic strategy for FH-associated brain dysfunction.
- Open Access
- 1 January 2026
- Published by Tikinet Edicao Ltda. - EPP in Clinical and Biomedical Research
- Vol. 46
Saúde Mental e Qualidade de Vida em Estudantes Brasileiros de Mestrado e Doutorado: Um Estudo Transversal
Introdução: Embora os ambientes acadêmicos sejam amplamente reconhecidos como contextos de alto estresse, ainda há escassez de pesquisas que investiguem essa questão. Objetivo: Determinar as taxas de sintomas depressivos, de ansiedade, burnout e qualidade de vida bem como investigar os fatores associados a esses desfechos. Métodos: Estudo transversal por meio de um questionário online com 927 estudantes de mestrado e doutorado de diferentes regiões do Brasil. Avaliou-se sintomas de ansiedade, depressão, exaustão emocional e qualidade de vida por meio de escalas validadas. Resultados: Sintomas moderados a graves de ansiedade e depressão foram relatados por 46% (média = 10,97 ± 6,63) e 52% (média = 9,42 ± 5,56) dos participantes, respectivamente, enquanto 51,0% apresentavam risco iminente de burnout. A qualidade de vida geral foi baixa (média = 16,39 ± 5,90), e 35% avaliaram sua saúde mental como ruim ou muito ruim. Idade mais jovem e histórico de transtorno psiquiátrico foram associados a maior gravidade dos sintomas e menor qualidade de vida. Conclusão: Nossos achados evidenciam uma importante crise de saúde mental entre estudantes de pós-graduação, ressaltando a necessidade de políticas institucionais voltadas à promoção da saúde mental e do bem-estar geral dos estudantes brasileiros.
- 1 January 2026
- Published by Tikinet Edicao Ltda. - EPP in Clinical and Biomedical Research
- Vol. 46
Open AccessSaúde Mental e Qualidade de Vida em Estudantes Brasileiros de Mestrado e Doutorado: Um Estudo Transversal
Introdução: Embora os ambientes acadêmicos sejam amplamente reconhecidos como contextos de alto estresse, ainda há escassez de pesquisas que investiguem essa questão. Objetivo: Determinar as taxas de sintomas depressivos, de ansiedade, burnout e qualidade de vida bem como investigar os fatores associados a esses desfechos. Métodos: Estudo transversal por meio de um questionário online com 927 estudantes de mestrado e doutorado de diferentes regiões do Brasil. Avaliou-se sintomas de ansiedade, depressão, exaustão emocional e qualidade de vida por meio de escalas validadas. Resultados: Sintomas moderados a graves de ansiedade e depressão foram relatados por 46% (média = 10,97 ± 6,63) e 52% (média = 9,42 ± 5,56) dos participantes, respectivamente, enquanto 51,0% apresentavam risco iminente de burnout. A qualidade de vida geral foi baixa (média = 16,39 ± 5,90), e 35% avaliaram sua saúde mental como ruim ou muito ruim. Idade mais jovem e histórico de transtorno psiquiátrico foram associados a maior gravidade dos sintomas e menor qualidade de vida. Conclusão: Nossos achados evidenciam uma importante crise de saúde mental entre estudantes de pós-graduação, ressaltando a necessidade de políticas institucionais voltadas à promoção da saúde mental e do bem-estar geral dos estudantes brasileiros.
- 31 October 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (4) , 4827-4850
Metabolomics in stress-related disorders: a systematic review and bioinformatics analysis
Stress-related disorders, including major depressive disorder (MDD), bipolar disorder (BD), and post-traumatic stress disorder (PTSD), share complex biological mechanisms and overlapping symptoms, posing challenges for diagnosis and treatment. This in silico study aimed to identify metabolomic patterns and explore dysfunctional metabolic pathways that are common and specific within a transdiagnostic psychiatric sample. A systematic review was conducted to identify metabolomic studies using mass spectrometry on blood samples from patients with MDD, BD, and PTSD. Study screening was performed using Rayyan, and metabolite codes were retrieved from the HMDB and ChEBI databases. Identified metabolites were classified using the R software, and metabolic pathway enrichment analysis was conducted in MetaboAnalyst. Thirteen eligible studies were identified, reporting 583 metabolites. Among these, four metabolites—arginine, inosine, 5-oxoproline (5-OP), and pyruvic acid—were consistently altered across disorders. Bioinformatics analysis revealed key metabolic pathways primarily related to amino acid, energy, carbohydrate, and lipid metabolism, suggesting shared biological mechanisms. These findings reinforce the transdiagnostic nature of metabolic dysfunction in psychiatric disorders and may contribute to the development of personalized therapeutic strategies and biomarker panels for improved diagnosis and treatment.
- 31 October 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (4) , 4827-4850
Metabolomics in stress-related disorders: a systematic review and bioinformatics analysis
Stress-related disorders, including major depressive disorder (MDD), bipolar disorder (BD), and post-traumatic stress disorder (PTSD), share complex biological mechanisms and overlapping symptoms, posing challenges for diagnosis and treatment. This in silico study aimed to identify metabolomic patterns and explore dysfunctional metabolic pathways that are common and specific within a transdiagnostic psychiatric sample. A systematic review was conducted to identify metabolomic studies using mass spectrometry on blood samples from patients with MDD, BD, and PTSD. Study screening was performed using Rayyan, and metabolite codes were retrieved from the HMDB and ChEBI databases. Identified metabolites were classified using the R software, and metabolic pathway enrichment analysis was conducted in MetaboAnalyst. Thirteen eligible studies were identified, reporting 583 metabolites. Among these, four metabolites—arginine, inosine, 5-oxoproline (5-OP), and pyruvic acid—were consistently altered across disorders. Bioinformatics analysis revealed key metabolic pathways primarily related to amino acid, energy, carbohydrate, and lipid metabolism, suggesting shared biological mechanisms. These findings reinforce the transdiagnostic nature of metabolic dysfunction in psychiatric disorders and may contribute to the development of personalized therapeutic strategies and biomarker panels for improved diagnosis and treatment.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Effects of Metformin Administration on Behavioral and Biochemical Parameters in a Familial Hypercholesterolemia Mouse Model
Background: Low‐density lipoprotein (LDL) is responsible for the transport of cholesterol to peripheric tissues (Cortes et al. 2014), and it enters the cells via LDL receptors (LDLr) (Luo, Yang, Song 2020). Cholesterol metabolism alterations, i.e., hypercholesterolemia are well‐known cardiovascular risk factors and have also been linked to cognitive and behavioral alterations (De Oliveira et al. 2011, Sparks et al. 1990, WHO 2008). Familial hypercholesterolemia (FH) is a prevalent disease caused by dysfunctions of cholesterol metabolism (Akioyamen et al. 2017), and several reports show its connection to neuroinflammation (Ariza et al. 2016, De Oliveira et al. 2020). Recent studies associate mTOR inhibition with conservation of blood‐brain barrier integrity, cognitive damage attenuation, and systemic and cerebral inflammation reduction in dementia and FH animal models (Jahrling et al. 2018, Van Skike et al. 2018). In this regard, Metformin presents critical therapeutic potential because it inhibits mTOR through AMPK.Objective: Evaluation of Metformin treatment on cognitive disturbances and central and peripheric biochemical parameters in C57BL/6 LDLr deficient (LDLr‐/‐) mice.Method: LDLr‐/‐ and wild‐type (WT) male mice (3‐month‐old, 20‐3 g) received a daily oral administration via gavage of Metformin (200 mg/kg) or Saline for 30 days. All animals were weighed weekly. Mice were submitted to behavioral tasks in the last week of treatment. Following the last day of treatment, animals fasted for 12 hours and were euthanized by cardiac exsanguination. Heparinized plasma was used to determine total cholesterol and triglyceride levels. Another cohort of animals was perfused with paraformaldehyde to collect fixed total brains, which were used in immunofluorescence assays for labeling glial fibrillary acidic protein (GFAP).Result: LDLr‐/‐ mice showed higher total cholesterol levels compared to WT groups. Metformin treatment increased triglyceride levels and decreased total body weight in LDLr‐/‐ mice in comparison to Saline administration. LDLr‐/‐ mice showed hyperlocomotive activity, cognitive damage, and a depressed phenotype, which was in parts attenuated by Metformin treatment. Metformin treatment ameliorated astrogliosis in the hippocampus of LDLr‐/‐ mice.Conclusion: Metformin treatment showed a promising effect on the memory impairment and astrocyte reactivity observed in LDLr‐/‐ mice, which was not via a cholesterol‐lowering outcome.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessEffects of Metformin Administration on Behavioral and Biochemical Parameters in a Familial Hypercholesterolemia Mouse Model
Background: Low‐density lipoprotein (LDL) is responsible for the transport of cholesterol to peripheric tissues (Cortes et al. 2014), and it enters the cells via LDL receptors (LDLr) (Luo, Yang, Song 2020). Cholesterol metabolism alterations, i.e., hypercholesterolemia are well‐known cardiovascular risk factors and have also been linked to cognitive and behavioral alterations (De Oliveira et al. 2011, Sparks et al. 1990, WHO 2008). Familial hypercholesterolemia (FH) is a prevalent disease caused by dysfunctions of cholesterol metabolism (Akioyamen et al. 2017), and several reports show its connection to neuroinflammation (Ariza et al. 2016, De Oliveira et al. 2020). Recent studies associate mTOR inhibition with conservation of blood‐brain barrier integrity, cognitive damage attenuation, and systemic and cerebral inflammation reduction in dementia and FH animal models (Jahrling et al. 2018, Van Skike et al. 2018). In this regard, Metformin presents critical therapeutic potential because it inhibits mTOR through AMPK.Objective: Evaluation of Metformin treatment on cognitive disturbances and central and peripheric biochemical parameters in C57BL/6 LDLr deficient (LDLr‐/‐) mice.Method: LDLr‐/‐ and wild‐type (WT) male mice (3‐month‐old, 20‐3 g) received a daily oral administration via gavage of Metformin (200 mg/kg) or Saline for 30 days. All animals were weighed weekly. Mice were submitted to behavioral tasks in the last week of treatment. Following the last day of treatment, animals fasted for 12 hours and were euthanized by cardiac exsanguination. Heparinized plasma was used to determine total cholesterol and triglyceride levels. Another cohort of animals was perfused with paraformaldehyde to collect fixed total brains, which were used in immunofluorescence assays for labeling glial fibrillary acidic protein (GFAP).Result: LDLr‐/‐ mice showed higher total cholesterol levels compared to WT groups. Metformin treatment increased triglyceride levels and decreased total body weight in LDLr‐/‐ mice in comparison to Saline administration. LDLr‐/‐ mice showed hyperlocomotive activity, cognitive damage, and a depressed phenotype, which was in parts attenuated by Metformin treatment. Metformin treatment ameliorated astrogliosis in the hippocampus of LDLr‐/‐ mice.Conclusion: Metformin treatment showed a promising effect on the memory impairment and astrocyte reactivity observed in LDLr‐/‐ mice, which was not via a cholesterol‐lowering outcome.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S1)
Glial cell reactivity drives cognitive decline in LDLr‐/‐ mice: experimental evidences
Background: Familial hypercholesterolemia (FH) is a clinical condition characterized by increased plasma cholesterol levels, due to a mutation in the gene encoding the low‐density lipoprotein receptor (LDLr) in cells [Brown and Goldstein, 1984]. Importantly, clinical evidence indicates that FH negatively affects cognition and favors the development of neuropathologies [Ariza et al., 2016; Zambón et al, 2010], however, the mechanisms behind this relationship are still not fully understood. In this study we aimed to investigate the role of glial cell reactivity on the cognitive deficits related to the FH, as well as the possible neuroprotective effect of a pharmacological inhibitor of microglial cell activation.Method: Firstly, male 3‐months‐old and 14‐months‐old C57BL/6 wild‐type and LDLr knockout mice (LDLr‐/‐) mice brains were prepared for the evaluation of glial cell morphology by immunofluorescence. In addition, the mice’s hippocampus was removed to measure the immune content of synaptic and tight‐junctions proteins. Moreover, male and female 6‐months‐old C57BL/6 wild‐type and LDLr‐/‐ mice were treated with minocycline (50 mg/kg) or vehicle (saline) for four weeks. Afterwards, mice were submitted to behavioral tests.Result: Middle‐aged LDLr‐/‐ mice (14‐months‐old) exhibited increased microgliosis in hippocampus, which was correlated with morphological change of microglial cells and astrocytes in this same brain region. Also, middle‐aged LDLr‐/‐ mice presented a reduction in the immune content of synaptophysin‐1 in the hippocampus. Moreover, young adult (3‐months‐old) LDLr‐/‐ mice exhibited reduced immune content of PSD95 in the hippocampus. Finally, the administration of minocycline to 6‐months‐old LDLr‐/‐ mice ameliorated the performance of hypercholesterolemic mice in hippocampal‐dependent memory tasks, without modifying their locomotor activity and metabolic parameters.Conclusion: Taken together, our results demonstrated that FH alters the glial cell reactivity, which was associated with changes in synaptic proteins in the hippocampus. In addition, the pharmacological modulation of microglial cell reactivity ameliorated the hippocampal‐dependent memory in LDLr‐/‐ mice, suggesting that increased glial cell reactivity is a key event for HF‐related cognitive deficits.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S1)
Open AccessGlial cell reactivity drives cognitive decline in LDLr‐/‐ mice: experimental evidences
Background: Familial hypercholesterolemia (FH) is a clinical condition characterized by increased plasma cholesterol levels, due to a mutation in the gene encoding the low‐density lipoprotein receptor (LDLr) in cells [Brown and Goldstein, 1984]. Importantly, clinical evidence indicates that FH negatively affects cognition and favors the development of neuropathologies [Ariza et al., 2016; Zambón et al, 2010], however, the mechanisms behind this relationship are still not fully understood. In this study we aimed to investigate the role of glial cell reactivity on the cognitive deficits related to the FH, as well as the possible neuroprotective effect of a pharmacological inhibitor of microglial cell activation.Method: Firstly, male 3‐months‐old and 14‐months‐old C57BL/6 wild‐type and LDLr knockout mice (LDLr‐/‐) mice brains were prepared for the evaluation of glial cell morphology by immunofluorescence. In addition, the mice’s hippocampus was removed to measure the immune content of synaptic and tight‐junctions proteins. Moreover, male and female 6‐months‐old C57BL/6 wild‐type and LDLr‐/‐ mice were treated with minocycline (50 mg/kg) or vehicle (saline) for four weeks. Afterwards, mice were submitted to behavioral tests.Result: Middle‐aged LDLr‐/‐ mice (14‐months‐old) exhibited increased microgliosis in hippocampus, which was correlated with morphological change of microglial cells and astrocytes in this same brain region. Also, middle‐aged LDLr‐/‐ mice presented a reduction in the immune content of synaptophysin‐1 in the hippocampus. Moreover, young adult (3‐months‐old) LDLr‐/‐ mice exhibited reduced immune content of PSD95 in the hippocampus. Finally, the administration of minocycline to 6‐months‐old LDLr‐/‐ mice ameliorated the performance of hypercholesterolemic mice in hippocampal‐dependent memory tasks, without modifying their locomotor activity and metabolic parameters.Conclusion: Taken together, our results demonstrated that FH alters the glial cell reactivity, which was associated with changes in synaptic proteins in the hippocampus. In addition, the pharmacological modulation of microglial cell reactivity ameliorated the hippocampal‐dependent memory in LDLr‐/‐ mice, suggesting that increased glial cell reactivity is a key event for HF‐related cognitive deficits.